Secondary objectives
toxicity, tumour
SECONDARY, TUMOUR
Five secondary objectives have been defined: first, late toxicity CTCAE v 5.0 grade three or higher will be evaluated at 6 months post-treatment. Second, dosimetric efficacy will be assessed using the summed EQD2 dose to screen for superiority of delivered dose to tumour (and organs at risk), as compared to EBRT alone. Third, anti-tumour efficacy will be assessed using the prostate-specific antigen (PSA) response level. This parameter cannot be used to detect improved anti-tumour effect for the experimental combined treatment, but it can be used to detect a (highly unlikely) reduced anti-tumour effect. Fourth, the feasibility of QoL evaluation by using QLQ-C30 and prostate-specific QLQ-PR25 questionnaires for this specific patient group will be determined. Lastly, pharmacokinetic modelling will be used to further explore the selected dose levels and the kinetics of [